Literature DB >> 27195437

Biochemical and Clinical Predictive Approach and Time Point Analysis of Hepatobiliary Phase Liver Enhancement on Gd-EOB-DTPA-enhanced MR Images: A Multicenter Study.

Masahiro Okada1, Takamichi Murakami1, Ryohei Kuwatsuru1, Yuko Nakamura1, Hiroyoshi Isoda1, Satoshi Goshima1, Ryota Hanaoka1, Hiroki Haradome1, Yoshinobu Shinagawa1, Azusa Kitao1, Yasunari Fujinaga1, Nagaaki Marugami1, Masako Yuki1, Tomoaki Ichikawa1, Atsushi Higaki1, Masatoshi Hori1, Shinya Fujii1, Osamu Matsui1.   

Abstract

Purpose To identify biochemical factors associated with liver enhancement over time on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance (MR) images and predict the optimal time point of the hepatobiliary phase in various clinical settings. Materials and Methods This study was approved by the institutional review boards, and written informed consent was obtained from the 1903 patients enrolled. Simple and multiple logistic regression analyses were performed to investigate the biochemical factors associated with liver-to-spleen contrast (LSC) of at least 1.5 in the hepatobiliary phase. Changes in LSC and lesion-to-liver contrast (LLC) of lesions over time (at 5, 10, 15, and 20 minutes) were investigated with a linear mixed-effects model in patients and lesions. For LSC, the optimal cutoff value was determined with receiver operating characteristic analysis of the most significant variable. Differences in LSC and LLC were analyzed in various clinical settings. Results Ultimately, 1870 patients were evaluated, as 33 were excluded according to study criteria. Prothrombin (PT) activity, total bilirubin level (P = .020), and total cholesterol level (P = .005) were significantly associated with LSC of at least 1.5 at 20 minutes, and PT activity was identified as the most significant factor (odds ratio, 1.271; 95% confidence interval: 1.109, 1.455; P = .001). LSC of at least 1.5 at 20 minutes with PT activity of at least 86.9% and less than 86.9% occurred in 555 of 626 patients (88.6%) and 388 of 575 patients (67.5%), respectively. Satisfactory liver enhancement at 20 minutes was significantly more likely to be achieved by patients with hepatitis B virus than by those with hepatitis C virus (P < .001) and by patients with metastasis than by those with hepatocellular carcinoma (P < .001). No significant difference in LLC was observed in patients examined at 1.5 and 3.0 T (P = .133). Conclusion Hepatic enhancement is significantly associated with PT activity, total bilirubin level, and total cholesterol level. PT activity of at least 86.9% could be used to shorten examination times at Gd-EOB-DTPA-enhanced MR imaging. © RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27195437     DOI: 10.1148/radiol.2016151061

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  10 in total

1.  Preoperative Prediction of Microvascular Invasion Risk Grades in Hepatocellular Carcinoma Based on Tumor and Peritumor Dual-Region Radiomics Signatures.

Authors:  Fang Hu; Yuhan Zhang; Man Li; Chen Liu; Handan Zhang; Xiaoming Li; Sanyuan Liu; Xiaofei Hu; Jian Wang
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

2.  Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.

Authors:  Osman Öcal; Bora Peynircioglu; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Bernhard Gebauer; Christoph J Zech; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alberto Benito; Kerstin Schütte; Antonio Gasbarrini; Ricarda Seidensticker; Moritz Wildgruber; Maciej Pech; Peter Malfertheiner; Jens Ricke; Max Seidensticker
Journal:  Eur Radiol       Date:  2021-08-31       Impact factor: 5.315

3.  Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.

Authors:  Osman Öcal; Michael Ingrisch; Muzaffer Reha Ümütlü; Bora Peynircioglu; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Bernhard Gebauer; Christoph J Zech; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alberto Benito; Maciej Pech; Peter Malfertheiner; Jens Ricke; Max Seidensticker
Journal:  Br J Cancer       Date:  2021-10-22       Impact factor: 7.640

4.  T1 reduction rate with Gd-EOB-DTPA determines liver function on both 1.5 T and 3 T MRI.

Authors:  Verena Carola Obmann; Damiano Catucci; Annalisa Berzigotti; Christoph Gräni; Lukas Ebner; Johannes Thomas Heverhagen; Andreas Christe; Adrian Thomas Huber
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

Review 5.  Diagnosis of Hepatocellular Carcinoma Using Gd-EOB-DTPA MR Imaging.

Authors:  Takamichi Murakami; Keitaro Sofue; Masatoshi Hori
Journal:  Magn Reson Med Sci       Date:  2021-08-21       Impact factor: 2.760

Review 6.  Assessment of Liver Function With MRI: Where Do We Stand?

Authors:  Carolina Río Bártulos; Karin Senk; Mona Schumacher; Jan Plath; Nico Kaiser; Ragnar Bade; Jan Woetzel; Philipp Wiggermann
Journal:  Front Med (Lausanne)       Date:  2022-04-06

7.  MELIF, a Fully Automated Liver Function Score Calculated from Gd-EOB-DTPA-Enhanced MR Images: Diagnostic Performance vs. the MELD Score.

Authors:  Carolina Río Bártulos; Karin Senk; Ragnar Bade; Mona Schumacher; Jan Plath; Nico Kaiser; Isabel Wiesinger; Sylvia Thurn; Christian Stroszczynski; Abdelouahed El Mountassir; Mathis Planert; Jan Woetzel; Philipp Wiggermann
Journal:  Diagnostics (Basel)       Date:  2022-07-20

8.  Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR.

Authors:  Carla Caparroz; Alejandro Forner; Jordi Rimola; Anna Darnell; Ángeles García-Criado; Juan Ramón Ayuso; María Reig; Jordi Bruix; Carmen Ayuso
Journal:  Radiol Oncol       Date:  2022-08-14       Impact factor: 4.214

9.  Prediction of Sufficient Liver Enhancement on the Gadoxetate Disodium-enhanced Hepatobiliary Phase Imaging Using Transitional Phase Images and Albumin-bilirubin Grade.

Authors:  Yasuo Takatsu; Masafumi Nakamura; Satoshi Kobayashi; Tosiaki Miyati
Journal:  Magn Reson Med Sci       Date:  2020-05-27       Impact factor: 2.471

10.  Evaluation of liver function using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging based on a three-dimensional volumetric analysis system.

Authors:  Masashi Kudo; Naoto Gotohda; Motokazu Sugimoto; Tatsushi Kobayashi; Motohiro Kojima; Shinichiro Takahashi; Masaru Konishi; Ryuichi Hayashi
Journal:  Hepatol Int       Date:  2018-06-02       Impact factor: 6.047

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.